Octreotide
Also known as: Sandostatin, SMS 201-995
Octreotide (also called Sandostatin or SMS 201-995) is an FDA-approved somatostatin analog. Octreotide is a synthetic cyclic octapeptide analog of somatostatin, engineered with D-amino acid substitutions and a disulfide-constrained ring that resist enzymatic degradation and extend the half-life from the roughly two minutes of native somatostatin to about ninety minutes.
For research use only.
Key Facts
- CAS
- 83150-76-9
- Molecular Weight (MW)
- 1019.3 g/mol
- Half-life
- ~1.7 hours (sc); depot has prolonged release
- FDA status
- Approved
- Administration Route
- Subcutaneous / Intramuscular (LAR)
- Frequency
- Three times daily (immediate-release) or monthly (LAR)
- Last updated
- Aug 30, 2026
- Reviewed
- Aug 30, 2026
- Targets
- SSTR2SSTR5
Vendor price snapshot
Each vendor's price is the median price per mg of its own listings; with fewer than 3 vendors there is no typical range. From public vendor listings collected in Dec 2025, so confirm the live price on the vendor site. Peptide Library does not sell peptides.
- Vendors listing this peptide
- 1
- Listed offers
- 1
- Price per mg
- $26.00/mg
Research summary
Synthetic cyclic octapeptide analog of somatostatin, engineered to resist degradation so its half-life is roughly ninety minutes rather than the two minutes of the natural hormone. FDA-approved for acromegaly, for symptom control in metastatic carcinoid tumours, and for the profuse watery diarrhoea of VIPoma. Because somatostatin is a broad inhibitory signal, it also suppresses insulin, glucagon and several gut hormones. A prescription medicine.
Peptide Library's Octreotide profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
Protocol
- Dosage Range
- 50-200 mcg three times daily (immediate-release) or 10-30 mg monthly (LAR depot)
- Frequency
- Three times daily (immediate-release) or monthly (LAR)
- Cycle
- Long-term use as prescribed
- Administration Route
- Subcutaneous / Intramuscular (LAR)
- Reconstitution Guide
- LAR formulation requires reconstitution per package insert
- Injection Sites
- Abdomen (sc)Gluteal (IM LAR)
- Concentration Example
- LAR: 10 mg, 20 mg, or 30 mg per injection (monthly)
- Timing Notes
- Inject subcutaneously (immediate-release) or intramuscularly (LAR depot)
- Expected Onset
- Symptom improvement typically seen within days to weeks
Not yet checked against primary sources
These figures are compiled from earlier reference material. They have not been verified against FDA labelling, registered trials or published literature, no citation is attached to them, and none of them is a recommended dose. Octreotide is queued for dosage evidence review.
Compare reported doses across the whole librarySequence & molecular data
| Molecular formula | C49H66N10O10S2 |
|---|---|
| Molecular weight | 1019.3 g/mol |
| CAS number | 83150-76-9 |
| Half-life | ~1.7 hours (sc); depot has prolonged release |
| Appearance | Solution and long-acting depot |
| Formulation | Solution |
| PubChem CID | 448601 |
| FDA UNII | RWM8CCW8GP |
| ChEMBL | CHEMBL1680 |
| DrugBank | DB00104 |
Identifiers link to the public PubChem, FDA Substance Registration (UNII), ChEMBL and DrugBank records for the same entity.
Science
Mechanism of Action
Octreotide is a synthetic cyclic octapeptide analog of somatostatin, engineered with D-amino acid substitutions and a disulfide-constrained ring that resist enzymatic degradation and extend the half-life from the roughly two minutes of native somatostatin to about ninety minutes. It binds somatostatin receptor subtypes 2 and 5 with high affinity, and these are Gi-coupled, so activation lowers cyclic AMP and suppresses hormone secretion. The consequences are broad because somatostatin is a general inhibitory signal: growth hormone falls, as do insulin, glucagon and a range of gut hormones including gastrin, secretin and vasoactive intestinal peptide. It also reduces splanchnic blood flow, which is the basis for its use in variceal bleeding.
Origin
Synthetic cyclic octapeptide analog of somatostatin.
Targets
Studies
- Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly
- Octreotide and direct/indirect lung injury
- Octreotide and Octreotide-derived delivery systems
- Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995)
- Octreotide for acromegaly treatment: a reappraisal
Regulatory & research status
Octreotide is an FDA-approved product for specific labelled indications. Approval does not extend to the research contexts described on this page, and approved products are prescription medicines.
| FDA status | Approved |
|---|---|
| Availability | Prescription-Only |
| WADA (sport) | Permitted |
| Library classification | FDA-Approved |
Benefits
Octreotide side effects
Side Effects
- Gallstones
- Hyperglycemia or hypoglycemia
- GI cramps
- Injection-site pain
Storage & stability
Lyophilized (freeze-dried) peptide powder is far more stable than the reconstituted solution. Keep sealed vials cold, dry and away from light; long-term storage is typically frozen, with short-term refrigeration for vials in use.
Once reconstituted in bacteriostatic water, keep the solution refrigerated, avoid repeated freeze–thaw cycles and agitation, and label the vial with the reconstitution date and concentration. Discard any solution that turns cloudy or shows particulates.
Degradation rates differ by sequence: peptides containing methionine, cysteine, asparagine or glutamine are more prone to oxidation and deamidation, so shelf life after reconstitution is compound-specific rather than universal.
Read the full guide: how to store peptides before and after reconstitution →
Source: Manning MC, Chou DK, Murphy BM, Payne RW, Katayama DS. Stability of protein pharmaceuticals: an update. Pharm Res. 2010;27(4):544–575. (PMID 20143256). General guidance for research handling; not product-specific instructions.
Octreotide: frequently asked questions
What is Octreotide?
Synthetic cyclic octapeptide analog of somatostatin, engineered to resist degradation so its half-life is roughly ninety minutes rather than the two minutes of the natural hormone. FDA-approved for acromegaly, for symptom control in metastatic carcinoid tumours, and for the profuse watery diarrhoea of VIPoma. Because somatostatin is a broad inhibitory signal, it also suppresses insulin, glucagon and several gut hormones. A prescription medicine.
How does Octreotide work?
Octreotide is a synthetic cyclic octapeptide analog of somatostatin, engineered with D-amino acid substitutions and a disulfide-constrained ring that resist enzymatic degradation and extend the half-life from the roughly two minutes of native somatostatin to about ninety minutes. It binds somatostatin receptor subtypes 2 and 5 with high affinity, and these are Gi-coupled, so activation lowers cyclic AMP and suppresses hormone secretion.
Is Octreotide FDA approved?
Yes. Octreotide is approved by the FDA, and approved products are prescription medicines. Approval is always for specific indications studied in clinical trials, so an approved status does not mean the compound is approved for every use it is discussed for. Research-chemical material sold under the same name is not the approved product.
What is the half-life of Octreotide?
Reported half-life for Octreotide is ~1.7 hours (sc); depot has prolonged release. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.
Is Octreotide banned in sport?
Octreotide is recorded here as permitted in sport. Anti-doping status is revised annually, so athletes subject to testing should confirm against the current WADA Prohibited List before use.
What peptides are similar to Octreotide?
Compounds most often compared with Octreotide include Lanreotide, Pasireotide, Dulaglutide and Exenatide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- FDA label — SandostatinExternal reference
- Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly — Clin Pharmacokinet, 2025External reference
- Octreotide and direct/indirect lung injury — Res Pharm Sci, 2025External reference
- Octreotide and Octreotide-derived delivery systems — J Drug Target, 2023External reference
- Inhibition of human exocrine pancreatic secretion by the long-acting somatostatin analogue octreotide (SMS 201-995) — Aliment Pharmacol Ther, 1992External reference
- Octreotide for acromegaly treatment: a reappraisal — Expert Opin Pharmacother, 2013External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Aug 30, 2026 · Version 1
This Octreotide profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track Octreotide research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →